Current Issues of Pharmacy and Medical Sciences

Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis ...

Curr Issues Pharm Med Sci., Vol. 27, No. 1, Pages 37-40

Marcin Dziedzic1, Ewelina Orłowska2, Kinga Gaweł3, Magdalena Zawadzka1, Anna Bednarek-Skublewska4, Janusz Solski1

1 Department of Laboratory Diagnostics, Medical University of Lublin

2 Department of Nephrology and Hypertension, Provincial Hospital of Lublin.

Department of Pharmacology and Pharmacodynamics, Medical University of Lublin

4 Department of Nephrology, Medical University of Lublin

DOI: 10.2478/cipms-2014-0010


Plasma levels of catecholamines and asymmetric dimethylarginine levels as predictive values of mortality among hemodialysis patients


The aim of the study was to assess plasma concentration of catecholamines and asymmetric dimethyl arginine levels and a possible relationship to predict the mortality rates among hemodialysis patients. The study population comprised 27 subjects, aged 65-70 years. Each patient underwent dialysis thrice a week. Furthermore, the median duration of hemodialysis was 3.5 years. Based on the conducted research, it can be concluded that the concentrations of adrenaline and the level of asymmetric dimethylarginine have predictive value of mortality among hemodialysis patients. Of note, lowering plasma asymmetric dimethylarginine concentration may represent therapeutic target for prevention of progressive renal damage.


Full Text


catecholamines, asymmetric dimethylarginine, hemodialysis, renal failure


  1. Agarwal R. et al.: Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am. J. Med., 115, 291, 2003.
  2. Aldámiz-Echevarría L., Andrade F.: Asymmetric dimethylarginine, endothelial dysfunction and renal disease. Int. J. Mol. Sci.,13, 11288, 2012.
  3. Alsagaff M.Y. et al.: Asymmetric dimethylarginine: a novel cardio­vascular risk factor in end-stage renal disease. J. Int. Med. Res., 40, 340, 2012.
  4. Arici M., Walls J.: End-stage renal disease, atherosclerosis, and car­diovascular mortality: is C-reactive protein the missing link? Kidney Int., 59, 407, 2001.
  5. Bassareo P.P. et al.: Urinary NGAL and hematic ADMA levels: an early sign of cardio-renal syndrome in young adults born preterm? J. Matern. Fetal Neonatal Med., 26, 80, 2013.
  6. Bassareo P.P. et al.: Could ADMA levels in young adults born preterm predict an early endothelial dysfunction? Int. J. Cardiol., 159, 217, 2012.
  7. De Jager D.J. et al.: Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA, 302, 1782, 2009.
  8. Goonasekera C.D. et al.: Nitric oxide synthase inhibitors and hyper­tension in children and adolescents. J. Hypertens., 15, 901, 1997.
  9. Guerin A, Pannier B, London G.: Atherosclerosis versus arterial stiffness in advanced renal failure. Adv. Cardiol.,44, 187, 2007.
  10. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 39, 1, 2002.
  11. Kielstein J.T. et al.: Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol., 13, 170, 2002.
  12. Kielstein J.T. et al.: Asymmetric dimethylarginine plasma concentra­tions differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol., 10, 594, 1999.
  13. Kielstein J.T. et al.: Subpressor dose asymmetric dimethylarginine modulates renal function in humans through nitric oxide synthase inhibition. Kidney Blood Press. Res., 27, 143, 2004.
  14. Koch M. et al.: Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol. Dial. Transplant., 12, 1187, 1997.
  15. Luyckx V.A., Brenner B.M. Low birth weight, nephron number and kidney disease. Kidney Int., 97, 68, 2005.
  16. Mallamaci F. et al.: Analysis of the relationship between norepineph­rine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J. Am. Soc. Nephrol., 15, 435, 2004.
  17. Nakayama Y. et al.: Asymmetric dimethylarginine accumulates in the kidney during ischemia/reperfusion injury. Kidney Int., 9, 1, 2013.
  18. Perticone F. et al.: Endothelial dysfunction, ADMA and insulin resistance in essential hypertension. Int. J. Cardiol., 142, 236, 2010.
  19. Raptis V., Kapoulas S., Grekas D.: Role of asymmetrical dimethy­larginine in the progression of renal disease. Nephrology (Carlton), 18, 11, 2013.
  20. Rocha M.S. et al.: Asymmetric dimethylarginine in adults with cystathionine β-synthase deficiency. Atherosclerosis, 222, 509, 2012.
  21. Rodriguez M.M. et al.: Comparative renal histomorphometry: a case study of oligonephropathy of prematurity. Pediatr. Nephrol., 20, 945, 2005.
  22. Rutkowski B. et al.: Raport o stanie leczenia nerkozastępczego w Polsce 2009. Drukonsul, Gdańsk 2010.
  23. Sarnak M.J., Levey A.S.: Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J. Thromb. Thrombolysis, 10, 169, 2000.
  24. Schwarz P. et al.: Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves. Circ. Res., 77, 841, 1995.
  25. Sesti G. et al.: A functional variant of the dimethylarginine dimethy­laminohydrolase-2 gene is associated with chronic kidney disease. Atherosclerosis, 231, 141, 2013.
  26. Sibal L. et al.: The role of asymmetric dimethylarginine (ADMA) in endothelial dysfunction and cardiovascular disease. Curr. Cardiol. Rev., 6, 82, 2010.
  27. Sydow K. et al.: Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin. Chem., 56, 111, 2010.
  28. Tripepi G. et al.: Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin. J. Am. Soc. Nephrol., 6, 1714, 2011.
  29. U.S. Renal Data System, USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2013.
  30. Ueda S. et al.: Asymmetric dimethylarginine may be a missing link between cardiovascular disease and chronic kidney disease. Neph­rology, 12, 582, 2007.
  31. Wilcken D.E. et al.: Asymmetric dimethylarginine (ADMA) in vascular, renal and hepatic disease and the regulatory role of l-argi­nine on its metabolism. Mol. Genet. Metab., 91, 309, 2007.
  32. Zoccali C. et al.: Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease. J. Am. Soc. Nephrol., 13, 490, 2002.
  33. Zoccali C. et al:. Inflammation is associated with carotid atherosc­lerosis in dialysis patients. J. Hypertens., 18, 1207, 2000.


April 2020

Mon Tue Wed Thu Fri Sat Sun
    01 02 03 04 05
06 07 08 09 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30